Oniria Therapeutics is a biotech company focused in the field of precision oncology. It develops first-in-class therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product, ONR-001 is an oral small molecule that allosterically activates TET2, a master epigenetic enzyme, causing tumor cells to enter a dormant state and even die. It is indication agnostic and can be used at all stages of the disease. Currently we already have results of in-vivo efficacy in xenofraft models of Acute Myeloid Leukemia, Melanoma and Colorectal Cancer.